Objective: To evaluate the safety and efficacy of two intralesional doses of recombinant human interferon-beta (r-hIFN-beta: Rebif X, Ares Serono), given 3 times a week for 3 weeks, in the treatment of condyloma acuminatum. Design: A randomised, double-blind, within-patient, placebo-controlled study. Subjects: 25 patients (24 males, 1 female) with a history of condyloma acuminatum. Twenty had failed previous treatment for condyloma acuminatum. In each patient, 3 distinct lesions were selected for treatmnent. Each selected lesion was randomly assigned to receive intralesionally one of the following: r-hIFN-beta 33,000 lU/day, r-hIFN-beta 1 x 106 IU/day, or matching placebo. Setting: Institut Alfred Fournier, Paris, France. Outcome measures: Response was evaluated colposcopically at the end of treatment (day 22) and 5 weeks later (month 2). Complete response (CR) was defined as disappearance of the treated lesion. Partial response (PR) was defined as at least a 50% reduction in size, but not disappearance of the treated lesion. Results: The higher dose of 1 x 106 IU achieved significantly more complete and partial remissions than placebo, both by the end of treatment, and 5 weeks later. Conclusions: r-hIFN-beta appears to be safe and effective when administered intralesionally to patients with condyloma acuminatum. Most of the treated patients had failed previous treatments and were therefore a resistant population.
Introduction
Human papilloma viruses (HPV) are now the most common sexually transmitted viral agents.' The infections may be asymptomatic or may be manifested in various benign or malignant lesions, most noticeably anogenital condyloma acuminatum (genital warts) and anogenital carcinoma. 23 The association of genital warts with cervical cancer is strong, independent of other risk factors and is consistent worldwide. 4 Although HPV infection causes substantial morbidity, conventional therapy for genital warts has involved local destruction of warty tissue. This succeeds in clearing visible disease in most patients, although recurrences are frequent, probably owing to persistent subclinical infection.5 Clinical trials have demonstrated that the intralesional administration of different interferon (IFN) preparations is more effective than that of placebo.$'2 Promising results have been reported with both IFN-alpha and IFN-beta, but the effects of intralesionally administered r-hIFN-beta in the treatment of this disease have not been examined carefully in placebo-controlled trials. To determine the safety and efficacy of intralesionally administered r-hIFN-beta in the treatment of condyloma acuminatum, we conducted a randomised, double-blind, within-patient, placebo-controlled, dose-comparative study.
Patients and methods
We studied 25 patients, of whom 24 were male and one was female (aged 18-38 years; mean 24.7) with a mean history of condyloma acuminatum of 391 days. The majority (20) had undergone previous treatment for condyloma acuminatum. This ranged from 1 to 7 treatments for a total of 49 for the whole group, most of them by CO2 laser. The mean duration of disease in these patients was 482 days.
Eligibility criteria for inclusion included colposcopically diagnosed vaginal, vulval or perianal (women) or penile (men) condyloma acuminatum, with three or more distinct lesions in the vagina or vulval-perianal area (women), or on the penile shaft, foreskin, or glans (men). Lesions selected for treatment had to be of similar size (> 3 mm in diameter), with a total area of < 1 cm2, separated from each other by at least 1 cm, preferably (but not necessarily) at the same site. None were located in the anal canal or distal urethra.
Patients with condylomatosis extending beyond the ano-genital area, or any invasive genital malignancy or any form of intraepithelial neoplasia of the genitals were also excluded.
The r-hIFN-beta, which was supplied by Ares-Serono, Aubonne, Switzerland, is glycosylated, being produced in genetically engineered Chinese hamster ovary cells, and consists of the native human IFN-beta amino acid sequence. It is essentially identical to natural IFN-beta in its physicochemical and biological properties. 
In each patient, three distinct lesions were selected for treatment. Each selected lesion was randomly assigned to receive intralesionally one of the following: r-hIFN-beta 33,000 lU/day, r-hIFN-beta 1 x 106 lU/day, or matching placebo. This design has the following advantages: it eliminates inter-patient variability, results in equal numbers of treated lesions per treatment at each time point, and gives every patient the opportunity to receive active treatment.
In order to reduce the risk of re-infection during the study, sexually active patients were instructed to abstain from unprotected sexual intercourse during the entire study and were provided with condoms.
Injections were administered intralesionally, in a volume of 0-1 ml, under colposcopic control at a minimum depth of approximately 2 mm, three times per week during a 19-day period. In all cases the injection was preceded by the administration of a local anaesthetic (lidocaine) to prevent pain on injection.
Response was evaluated colposcopically at the end of treatment (day 22) and 5 weeks later (month 2). Each lesion was measured directly in mm (that is, longest diameter and longest perpendicular diameter) and the area (mm2) was calculated from the two measurements. Complete response (CR) was defined as disappearance of the treated lesion. Partial response (PR) was determined by reduction in size, but not disappearance of the treated lesion. Four Recently, a randomised, double-blinl placebo-controlled trial involving 100 patien has demonstrated that systemically admini tered fibroblast IFN-beta, was effective in the long term eradication of anogenital condylomatous lesions.'5 The dose used was 2 x 106 IU/day for 10 days, given intramuscularly. Fifty one per cent of patients treated with IFNbeta showed a complete response, compared to 29% of placebo treated patients (p < 0.05).
All 24 patients who had responded to IFNbeta, remained lesion free at 1 year, while 12 of the 13 patients who had responded to placebo, had recurrent lesions, when followed up for the same period.
The use of intramuscular injections of IFNbeta was again investigated in a placebocontrolled study in 37 patients, classified according to site of lesion and HPV type.'6 No association was apparent between response and whether the lesion was associated with HPV 6, HPV 1 1 or HPV 16. Satisfactory results were achieved in treating vulval and vaginal condylomata as well as HPV-CIN II lesions, but the success rate was less satisfac-+ tory for flat HPV lesions of the cervix, espe-2. cially when associated with high-grade CIN. te
Intralesional administration of natural IFNed alpha was evaluated in an open study,9 in 7 which 7/10 patients had a significant reduction on in the size of their lesions, while five of these at experienced CR. No lesions that responded to IFN treatment recurred during a follow-up )st period of up to nine months. p-A large (n = 296), randomised, doubleLd. blind trial'0 compared intralesional IFN-alpha- 2b (1 x 106 IU, three times a week for three weeks) with placebo and found that IFN provided significantly better response (P < ,ly 0-001), although the frequency of adverse ns effects led the investigators to conclude that na IFN-alpha-2b was only fairly well tolerated. In ce similar studies'7 authors found a complete diso-appearance of all warts in 43.8% of patients. 
